Dr. Paul McKenzie retires as CEO and Managing Director of CSL effective February 10, 2026, after three years in the role and seven years with the company.12
Gordon Naylor, former CFO and President of Seqirus with 33 years at CSL, appointed interim CEO and Managing Director effective February 11, 2026.12
Naylor receives a one-off equity award valued at US$4.06 million, vesting after 12 months subject to performance, with no short-term or long-term incentives.12
The leadership change occurs one day before CSL's fiscal 2026 half-year earnings release, amid challenges like lower US vaccine demand implied in context.34
CSL shares have declined 37% over the past 12 months, underperforming the S&P/ASX 200 Index.1
Sources:
1. https://www.fool.com.au/2026/02/10/csl-names-gordon-naylor-interim-ceo-as-dr-paul-mckenzie-retires/
2. https://investors.csl.com/pdf/34e826de-672e-4027-b147-b647bb4aa602/Paul-McKenzie-retires-Gordon-Naylor-appointed-interim-CEO.pdf?Platform=ListPage
3. https://insights.citeline.com/scrip/scrip/leadership/csl-ceo-paul-mckenzie-exits-with-former-exec-gordon-naylor-stepping-in-NORBYKYG5JCVXFPS2QYR2IJSL4/
4. https://www.fiercepharma.com/pharma/csls-chief-executive-retires-ahead-earnings-former-seqirus-president-steps-interim-role